Ixekizumab was superior to adalimumab at 24 weeks in a head-to-head trial evaluating both skin and joint symptoms in patients with psoriatic arthritis and inadequate response to csDMARDs, say researchers writing in Annals of the Rheumatic Diseases last month.
A clinical trial presented at the Clinical Congress of Rheumatology West in San Diego last month shows that the oral JAK inhibitor tofacitinib improved the signs, symptoms and quality of life for patients with psoriatic arthritis who have not had an adequate response to DMARDs or TNF inhibitors.
In this installment of our psoriatic arthritis quiz, we focus on features associated with the five types of psoriatic arthritis. Can you identify all types of psoriatic arthritis and address how best to treat each condition?
A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.
A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.
While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.
In today's installment of our psoriatic arthritis quiz, we revisit some recently published studies and news headlines. What new treatment for psoriatic arthritis has gone before the FDA for approval? Test your knowledge on this and other recent headlines in this quiz.
The human monoclonal antibody was previously approved for the treatment of adults with plaque psoriasis in July 2017.
Janssen is seeking FDA approval of guselkumab (Tremfya) for adults with active psoriatic arthritis. If approved, it would become the second IL-23 inhibitor in the U.S. market.
Psoriatic arthritis can appear in a variety of ways from nail disease to peripheral joint pain. But, there are a few hallmark signs that can send a rheumatologist or rheumatology nurse in the right direction. In this Q&A, Linda Grinnell-Merrick, NP, discusses the ins and outs of a psoriatic arthritis diagnosis.
Psoriatic arthritis can manifest in a variety of ways from nail disease to peripheral joint pain. But, there are a few hallmark signs that can point a rheumatologist or rheumatology nurse in the right direction. In a presentation given at the Rheumatology Nurses Society annual meeting in August, Linda Grinnell-Merrick, NP, an allergy, immunology, and rheumatology nurse practitioner at the University of Rochester Medical Center, discussed the treatment of psoriatic arthritis.
In this installment of the psoriatic arthritis quiz, we focus on nail pitting and onycholysis. How familiar are you with the characteristics associated with these two conditions?
Can gluten-containing food products trigger a psoriatic arthritis flare? How well does the average psoriatic arthritis patient understand their condition? Learn more in today's psoriatic arthritis quiz.
In this slideshow we provide a quick update on the latest developments the anti-TNF treatments of rheumatoid arthritis, psoriatic arthrhitis, ankylosing spondylitis and other autoimmune conditions. Among the developments includes a new surprising use for etanercept (Enbrel, Amgen).
The FDA suggests only limited use of tofacitinib to treat rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis.
In today's health quiz, we highlight some of the most recent scientific advances in psoriatic arthritis research. Click here to test your knowledge.
In psoriatic arthritis, exhibiting different comorbidities may require different treatment regimens. In this installment of our monthly psoriatic arthritis quiz, we present a few different scenarios. How good are you at coming up with an effective treatment plan? Test your knowledge with this quiz.
The presence of carotid atherosclerosis in psoriasis and psoriatic arthritis patients is associated with an increased risk of having a cardiovascular event, researchers report.
A pair of phase 3 studies showed 20% symptomatic improvement in patients with psoriatic arthritis who were treated with guselkumab.
A trio of phase 3 psoriatic arthritis trials showed that 30 mg of apremilast, twice daily, increased the likelihood of achieving low disease activity or remission.
Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.
Three studies presented this weekend at EULAR in Madrid suggest that being overweight or obese can heighten the severity or arthritic disease.
